These patients are those who can probably benefit the most from attending the NPD outpatient service, as there is a therapeutic ‘window’ where the integrated nephrology/diabetology approach can: (I) optimize DKD therapy through the introduction of SGLT-2 inhibitors and/or GLP-1R agonists; (II) assess the individual cardiovascular risk of DKD patients by evaluating and properly managing arterial hypertension, urate levels and lipids. This evidence concerns the gene GLP1R and diabetic kidney disease.